Atlas FDA

TheraSphere

FDA premarket approval P200029/S004 · decided 2022-12-02

Approval details

PMA number
P200029
Supplement
S004
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Postapproval Study Protocol
Trade name
TheraSphere
Generic name
Microspheres radionuclide
Applicant
Boston Scientific Corporation
Date received
2022-11-02
Decision date
2022-12-02
Days to decision
30 days
Decision code
APPR
Product code
NAW
Advisory committee
Radiology
Expedited review
No
Location
Marborough, MA
Statement
Approval of the revised protocol for the post-approval study (PAS) protocol.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
TheraSphere 360™ Y-90 Management Platform (K262462)Boston Scientific Corporation2026-07-24
FARADRIVE™ Steerable Sheath (M004PF21M402) (K262165)Boston Scientific Corporation2026-07-24
OBSIDIO Conformable Embolic (K261488)Boston Scientific Corporation2026-07-24
WallFlex Esophageal Stent System;Agile Esophageal Over-the-Wire (OTW) Stent System (K261978)Boston Scientific Corporation2026-07-10
RIVOS™ EUS Access Device (M00553900) (K260428)Boston Scientific Corporation2026-06-17
MOSES Raydar™ (K260100)Boston Scientific Corporation2026-05-18
TruSelect™ 2.6 Microcatheter (K260771)Boston Scientific Corporation2026-05-15
Asurys Fluid Management System (K251273)Boston Scientific Corporation2026-03-27